SEC Form 4 · accession 0001209191-18-001959
Mersana Therapeutics, Inc. · MRSN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sara M. Nayeem
Director
Period of report
Jan 2, 2018
Accepted (ET)
Jan 4, 2018 · 4:31 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001442836
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $17.39 | Jan 2, 2018 | A | 3,560 | A | — | Jan 2, 2028 | Common Stock | 3,560 | 3,560 | D |
Explanation of responses
- F1The option becomes exercisable in equal quarterly installments on the last day of each calendar quarter of 2018.